bpc-157 for ulcerative colitis JPP No 5/2013 article 09 FDA Discusses Peptide Bulk Substances

Classified as a pentadecapeptide (15 amino acids), it functions as a signaling molecule in experimental models rather than an approved medical treatment

It activates the HGF/c-Met receptor pathway in the brain, promoting the formation of new synaptic connections (synaptogenesis)

Adding cagrilintide to tirzepatide Theoretical protocol (not clinically studied): If on tirzepatide 10-15mg: Stable on tirzepatide for 4+ weeks Continue tirzepatide at current dose Add cagrilintide 0.6mg weekly Standard cagrilintide titration to 2.4mg Rationale: Tirzepatide is dual GIP/GLP-1 (very powerful alone) Adding amylin pathway could theoretically enhance No clinical data on this combination Uncertain if additional benefit over tirzepatide alone Concerns: GI side effects may be severe (both slow gastric emptying) Tirzepatide already produces 15-22% weight loss alone Unclear if cagrilintide adds meaningful benefit Expensive combination Verdict: Wait for clinical data

It rinses away cleanly with water after application

Roth B, Schiro DB, Ohlsson B (2021) Diseases which cause generalized peripheral neuropathy: a systematic review